real peptides FAQ

Sequential administration outperforms simultaneous dosing in most published studies. TB-4 first (acute phase, 24–72 hours) to suppress inflammation and enhance migration, followed by growth factors (subacute phase, 4–10 days) to stimulate matrix synthesis once the inflammatory environment is controlled. A study in Journal of Orthopaedic Research found TB-4 → TGF-β sequential protocols increased cartilage thickness by 29% versus 14% for TGF-β monotherapy. The mechanism: TB-4 reduces MMP activity that would otherwise degrade newly synthesised matrix from growth factor stimulation.

Request a detailed impurity profile from the supplier. Multiple small peaks (<1% each) scattered across the chromatogram are normal and represent salt adducts, diastereomers, or minor oxidation products that don't affect biological activity. A single large secondary peak (>2%) indicates a specific contaminant. Most commonly a deletion sequence (LL-36 or LL-35) or an oxidized methionine variant. If the supplier cannot identify the impurity chemically, reject the batch. Uncharacterized peaks above 2% AUC introduce unknown variables into your assay that cannot be controlled or corrected.

Insert a 48-hour peptide washout period and assess whether Body Battery recharges to baseline (typically 75–85 for healthy adults). Persistent Body Battery depletion below 60 indicates cumulative stress load. Training volume, sleep debt, or psychological stress. Is outpacing recovery capacity. Peptides amplify endogenous repair, but if systemic resources are exhausted, the compounds have nothing to amplify. Garmin's stress tracking will often show elevated stress scores (above 50) throughout the day during these periods. Reduce training volume by 30–40%, prioritise sleep extension (aim for 8+ hours as confirmed by Garmin sleep logs), and reintroduce peptides at 70% of the previous dose after Body Battery stabilises above 70 for two consecutive nights.

This typically indicates incomplete TFA removal during lyophilization. Trifluoroacetic acid is used as an ion-pairing agent during reverse-phase HPLC purification. Residual TFA binds to cationic residues on LL-37 and adds 114 Da per molecule. A molecular weight 10–20 Da above 4493.3 suggests partial TFA adduction across the batch. While TFA doesn't significantly alter LL-37's antimicrobial mechanism, it does reduce solubility at neutral pH and can introduce cytotoxic effects in mammalian cell assays at concentrations above 0.1% w/w. Request the supplier re-lyophilize the peptide from an HCl or acetate solution to remove TFA.

Isolate whether the deficit is HPA axis-related (sustained cortisol dysregulation), inflammatory (elevated IL-6/TNF-alpha), or training-volume-related (accumulated mechanical stress unrelated to peptide washout). Measure cortisol awakening response on three consecutive mornings. If the spike from waking to 30 minutes post-waking is blunted or absent, HPA suppression may require another 14–21 days. If inflammatory markers are still elevated, consider that training intensity during the washout phase may be preventing cytokine normalization rather than peptide residuals being the cause.

Glutathione's antioxidant properties theoretically protect against oxidative stress from retinoid use, but no published studies directly examine this interaction. Practitioners generally recommend separating administration. Glutathione in morning/afternoon, topical retinoids at night. To avoid any theoretical interference with retinoid metabolism. Alpha-hydroxy acids don't mechanistically interact with glutathione pathways.

Document the deviation in your lab notebook with the exact reconstitution time and technique. Extended gentle swirling (90 seconds vs 30 seconds) doesn't cause aggregation. It's the force applied that matters, not the duration. If you swirled gently for 90 seconds, the peptide is fine. If you vortexed or shook the vial, even briefly, microaggregates may have formed. The conservative approach: run a single-dose pilot with the reconstituted solution and compare bioactivity against a freshly reconstituted control vial using your primary outcome measure. If results match within 10%, proceed; if they diverge, discard the vial and reconstitute fresh.

Establish a standardised background colour-coding system. Photograph Supplier A compounds against a white background, Supplier B against grey, for example. This visual differentiation prevents cross-contamination of documentation timelines when reviewing hundreds of images across a multi-month protocol. Include a reference card in each frame identifying the supplier, compound name, and your internal tracking code. When working with research-grade compounds from Real Peptides alongside other sources, the colour-coding system eliminates the 'which supplier's batch does this vial represent' question during post-protocol analysis.

Continue the dose for the full four weeks. The 2.5mg starting dose is intentionally subtherapeutic for most patients. Its purpose is receptor priming, not weight loss. Meaningful appetite suppression typically begins at 5mg or 7.5mg for individuals with higher baseline insulin resistance or BMI >35. If you escalate prematurely based on absence of effect in week two, you'll experience disproportionately worse nausea at the next dose level without shortening the overall timeline to therapeutic effect.

Don't mix them in the same syringe. Each peptide has a different pH stability range and different solubility profile. Combining them risks precipitation or peptide-peptide interactions that alter bioavailability. Administer each peptide from a separate syringe, spaced 5–10 minutes apart to allow independent absorption kinetics. For studies requiring identical administration timing, use separate injection sites (e.g., left abdomen for GHRP-2, right abdomen for BPC-157).

Stagger them by 90 minutes minimum. NAC (N-acetylcysteine) and glycine both use the same intestinal amino acid transporters as glutathione's constituent amino acids. Co-dosing creates competitive inhibition. None of the compounds reach full absorption potential. Dose glutathione first in the morning fasted state, then dose NAC 90 minutes later with a small meal, or reverse the order if NAC is your priority compound. Glycine can be dosed separately at night without interfering with morning glutathione protocols.

Reduce concentration incrementally. Irritation typically appears above 30 µg/mL in sensitive tissue. A 2018 dermatology safety study found that 10 µg/mL LL-37 hydrogel applied twice daily for 28 days produced no measurable irritation or sensitization in healthy volunteers. If irritation persists at lower concentrations, consider pH adjustment. LL-37 formulated at pH 6.5–7.0 shows significantly lower irritation potential than acidic or alkaline formulations.

Stop immediately. Properly reconstituted peptides should be clear and colourless. Cloudiness indicates protein aggregation (irreversible denaturation), and visible particles suggest contamination or precipitate formation. Neither is salvageable. The most common cause: injecting bacteriostatic water too forcefully, creating foam and shear stress that denatures the peptide structure. Reconstitute slowly along the vial wall, and allow 2–3 minutes for complete dissolution before drawing the first dose.

Don't. Baseline IGF-1, liver, and kidney function testing costs $150–300 but provides the only objective method to verify your peptides are working. Without baseline comparison, a week-8 IGF-1 of 180 ng/mL is uninterpretable. It could represent successful elevation from 120 ng/mL or failed elevation from 170 ng/mL. Retrospective baselining after noticing effects is impossible because you cannot un-start the protocol. If the stack isn't working, you'll waste 8–12 weeks and $400–800 in peptide costs before discovering it through subjective assessment alone. The biomarker panel pays for itself by catching protocol failures early enough to adjust dosing or verify peptide purity before significant time and money are lost.

Combination protocols are common in research settings. TB-4 addresses the inflammatory axis, while peptides like DSIP (Delta Sleep-Inducing Peptide) act on GABA-ergic pathways. Administer TB-4 in the morning and DSIP 30–60 minutes before intended sleep onset. The mechanisms are complementary, not overlapping. Research indicates synergistic SWS enhancement when anti-inflammatory and GABAergic pathways are both optimised, though no large-scale trials have quantified the effect size.

Discard lyophilised peptide if exposed to room temperature (20–25°C) for more than 48 hours; discard reconstituted peptide if left unrefrigerated for more than 2 hours. Room temperature accelerates hydrolysis and oxidation exponentially. What takes months at −20°C occurs within days at ambient conditions. The peptide may still appear as white powder or clear solution, but molecular degradation has already begun. Lyophilised GHRP-2 acetate tolerates brief ambient exposure during shipping (24–48 hours), but intentional room-temperature storage beyond this introduces unacceptable variance. For reconstituted solutions, the 2-hour threshold reflects bacterial growth risk in addition to chemical degradation.

Yes, but the constraints differ. Liposomal encapsulation protects glutathione from gastric acid and peptidases, but high-fat meals trigger bile secretion that destabilises phospholipid membranes. Dose liposomal glutathione 30–60 minutes before a low-fat meal (≤10g fat) to allow absorption before bile release peaks. If you must dose post-meal, wait 2–3 hours until bile secretion normalises. The liposomal advantage is real. Absorption studies show 2–3× higher plasma GSH levels compared to reduced glutathione. But meal composition still modulates delivery efficiency.

Verify selenium status before assuming glutathione supplementation has failed. Glutathione peroxidase (GPx), the enzyme responsible for glutathione's hepatoprotective effects, requires selenium as a cofactor. Without adequate selenium (>70 μg/L serum), supplemental glutathione cannot function optimally in hepatic tissue. A 2019 trial in Biological Trace Element Research found that combining glutathione 1,000 mg with selenium 200 μg daily reduced ALT by 24% in NAFLD patients, compared to 11% with glutathione alone.

GHRP-2 monotherapy at standard research doses (100–300mcg per injection, 2–3x daily) produces moderate IGF-1 elevation. Enough to support recovery and lean mass retention without the extreme IGF-1 peaks associated with MK-677 or combination protocols. Subjects without existing pattern hair loss or genetic predisposition can typically run 8–12 week GHRP-2 cycles without observable follicle effects. The lower IGF-1 ceiling means proportionally less 5-alpha reductase upregulation. If you're particularly concerned, pair GHRP-2 with topical minoxidil (5% solution applied to scalp nightly). Minoxidil's vasodilatory and anagen-extending effects counterbalance any minor DHT-mediated stress in sensitive follicles.

Reduce to the previous dose immediately and hold for an additional four weeks before attempting the escalation again. Persistent nausea (lasting >72 hours or interfering with daily function) signals that receptor adaptation hasn't completed at the current level. The standard protocol assumes a four-week adaptation window, but 15–20% of patients require six weeks at intermediate doses. Slowing titration is always preferable to discontinuing entirely. Most patients who discontinue due to GI side effects would have tolerated the medication if escalation had been decelerated.